Adamas Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ADAMAS PHARMA, and when can generic versions of ADAMAS PHARMA drugs launch?
ADAMAS PHARMA has two approved drugs.
There are twenty-eight US patents protecting ADAMAS PHARMA drugs.
There are forty-two patent family members on ADAMAS PHARMA drugs in eleven countries.
Summary for Adamas Pharma
| International Patents: | 42 |
| US Patents: | 28 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
| Patent Litigation for Adamas Pharma: | See patent lawsuits for Adamas Pharma |
| PTAB Cases with Adamas Pharma as patent owner: | See PTAB cases with Adamas Pharma as patent owner |
Drugs and US Patents for Adamas Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | 8,895,617 | See Plans and Pricing | See Plans and Pricing | ||||
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | RX | Yes | No | 8,895,614 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | 8,895,616 | See Plans and Pricing | See Plans and Pricing | ||||
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | RX | Yes | No | 9,867,791 | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Adamas Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Adamas Pharma | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | RE39069 | See Plans and Pricing |
| Adamas Pharma | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | RE39069 | See Plans and Pricing |
| Adamas Pharma | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-002 | Feb 16, 2018 | RE39069 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Adamas Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2782556 | See Plans and Pricing |
| Brazil | 112020003375 | See Plans and Pricing |
| Australia | 2010325960 | See Plans and Pricing |
| Canada | 2588296 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
